Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02239120 · ClinicalTrials.gov registry record · Phase 3
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
A Phase 3 study of Stroke and Secondary Prevention, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,390
- Enrollment target
- 20
- Study locations
NCT02239120 is a Phase 3 study of Stroke and Secondary Prevention that has completed, run by Boehringer Ingelheim. The registered enrollment target is 5,390 participants, below the 12,005-participant average among 454 other Stroke trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT02239120, a Phase 3 study of Stroke and Secondary Prevention, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,390 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is not mandatory. All Adverse Events (AEs), Serious Adverse Events (SAEs), outcome events will be recorded. The trial will conclude when the required number of stroke events are positively adjudicated which is estimated to take 3 years (including 2.5 years of enrollment).
Conditions Studied
Interventions
- DRUG optional ASA as comedication
- DRUG placebo to ASA
- DRUG placebo to optional ASA as comedication
- DRUG placebo to dabigatran etexilate
- DRUG ASA 100 mg
Study Locations (20)
California
- Westside Medical Associates of Los Angeles - Beverly Hills
- TriWest Research Associates, LLC - El Cajon
- University of California - Fresno
- Glendale Adventist Medical Center - Glendale
- Collaborative Neuroscience Network, LLC (CNS) - Long Beach
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- University of California Los Angeles - Los Angeles
- Huntington Hospital - Pasadena
- University of California - San Diego
- University of California - San Francisco
Colorado
- University of Colorado Denver - Aurora
- Colorado Neurological Institute - Englewood
- University of Colorado Denver - Fort Collins
- St. Mary's Hospital and Regional Medical Center - Grand Junction
Florida
- JEM Research Institute - Atlantis
- Boca Raton Regional Hospital - Boca Raton
- Tenet Florida Physician Services - Boynton Beach
- Nova Clinical Research, LLC - Bradenton
Arizona
- Bronislava Shafran, MD PC - Phoenix
Connecticut
- Hartford Hospital - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,390 participants |
| Start Date | 2014-11-27 |
| Est. Completion | 2018-08-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02239120
The ClinicalTrials.gov registry entry for NCT02239120 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5,390 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,005-participant average among 454 other Stroke trials with a reported enrollment target (55% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 5 interventions - of which optional ASA as comedication is the first listed.
NCT02239120 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT02239120 about?
NCT02239120 is a clinical study titled "Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)". This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with corona...
What is the current status of trial NCT02239120?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,390 participants. The study started on 2014-11-27. Estimated completion is 2018-08-14.
What conditions does trial NCT02239120 study?
This clinical trial studies the following conditions: Stroke, Secondary Prevention.
What interventions are being tested in trial NCT02239120?
The interventions under investigation include: optional ASA as comedication (DRUG), placebo to ASA (DRUG), placebo to optional ASA as comedication (DRUG), placebo to dabigatran etexilate (DRUG), ASA 100 mg (DRUG).
Who is sponsoring clinical trial NCT02239120?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02239120 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
-
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
ACTIVE NOT RECRUITING · Phase 3
-
Locomotor Experience Applied Post Stroke Trial
COMPLETED · Phase 3
-
Vitamin Therapy for Prevention of Stroke
COMPLETED · Phase 3
-
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
COMPLETED · Phase 3
-
Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.